Iron chelation therapy in the management of transfusion-related cardiac iron overload

Transfusion

Volumn 52, Issue 10, 2012, Pages 2256-2268

  Fernandes, Juliano Lara ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

CARDIAC IRON OVERLOAD; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; DRUG HALF LIFE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; IRON CHELATION; IRON OVERLOAD; MOLECULAR SIZE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SYSTOLIC DYSFUNCTION; THALASSEMIA MAJOR; TREATMENT RESPONSE;

BENZOATES; BLOOD TRANSFUSION; CARDIOMYOPATHY, DILATED; CHELATION THERAPY; CROSS-SECTIONAL STUDIES; DEFEROXAMINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84868272565     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03580.x     Document Type: Review

References (80)

1. Telfer P,. Update on survival in thalassemia major. Hemoglobin 2009; 33 (Suppl 1): S76-80.
2. Taher AT, Musallam KM, Inati A,. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009; 33 (Suppl 1): S46-57.
3. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y,. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010; 56: 1001-12.
4. Fernandes JL, Fabron A Jr, Verissimo M,. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica 2009; 94: 1776-7.
5. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ,. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-9.
6. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ,. On T2* magnetic resonance and cardiac iron. Circulation 2011; 123: 1519-28.
7. Liu P, Olivieri N,. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther 1994; 8: 101-10.
8. Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M,. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging 2011; 34: 56-9.
9. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ,. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10: 42.
10. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, Keren A,. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 2010; 3: 451-8.
11. Modell B, Darlison M,. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-7.
12. Porter JB,. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev 2009; 23 (Suppl 1): S3-7.
13. Brittenham GM,. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011; 364: 146-56.
14. Cappellini MD, Musallam KM, Taher AT,. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin 2009; 33 (Suppl 1): S58-69.
15. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG,. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977; 297: 418-23.
16. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S, Huehns ER,. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet 1984; 1: 392-3.
17. Flynn DM, Hoffbrand AV, Politis D,. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Birth Defects Orig Artic Ser 1982; 18: 347-53.
18. Freeman AP, Giles RW, Berdoukas VA, Walsh WF, Choy D, Murray PC,. Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med 1983; 99: 450-4.
19. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW,. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-73.
20. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA,. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 2001; 111: 349-54.
21. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M,. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005; 127: 1523-30.
22. Gabutti V, Piga A,. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36.
23. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR,. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-8.
24. Olivieri NF, Brittenham GM,. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-61.
25. Olivieri NF, Sher GD, MacKinnon JA,. The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1. Blood 1994; 84 (Suppl 1): 363a [abst 1436].
26. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L,. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) 1987; 295: 1509-12.
27. Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A, Malizia R, Borsellino Z, Capra M, D'Ascola DG, Magnano C, Gerardi C, Rigano P, Maggio A,. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study. Hemoglobin 2003; 27: 63-76.
28. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM,. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990; 336: 1275-9.
29. Hoyes KP, Porter JB,. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 1993; 85: 393-400.
30. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ,. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-20.
31. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M,. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28: 196-208.
32. Piga A, Gaglioti C, Fogliacco E, Tricta F,. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-96.
33. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A,. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-7.
34. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R,. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-44.
35. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P,. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009; 42: 247-51.
36. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V,. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009; 11: 20.
37. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A,. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011; 96: 41-7.
38. US Food and Drug Administration. FDA approves Ferriprox to treat patients with excess iron in the body. 2011. [cited 2011 Feb 15]. Available from: URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
39. European Medicines Agency. Ferriprox (deferiprone): summary of product characteristics. 2009.
40. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F,. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330-6.
41. Wonke B, Wright C, Hoffbrand AV,. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361-4.
42. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C,. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138: 130-8.
43. Kolnagou A, Kontoghiorghes GJ,. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30: 239-49.
44. Daar S, Pathare AV,. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006; 85: 315-9.
45. Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M,. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens. Eur J Haematol 2007; 78: 52-7.
46. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ,. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-84.
47. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ,. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10: 12.
48. Mamtani M, Kulkarni H,. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 2008; 141: 882-90.
49. Porter JB,. Deferasirox: an update. Hemoglobin 2009; 33 (Suppl 1): S70-75.
50. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R,. Safety, tolerability, and pharmacokinetics of icl670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565-72.
51. Novartis Pharmaceuticals UK Ltd. Exjade 125 mg, 250 mg, 500 mg dispersible tablets-summary of product characteristics. Electronic Medicines Compendium (eMC). 2011. [cited 2012 Feb 15]. Available from: URL: http://www.medicines.org.uk/emc/medicine/18805/SPC/-
52. Glickstein H, El RB, Shvartsman M, Cabantchik ZI,. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005; 106: 3242-50.
53. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI,. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006; 108: 3195-203.
54. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C,. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year epic study. Leuk Res 2010; 34: 1143-50.
55. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB,. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the epic trial. Blood 2010; 116: 2448-54.
56. Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL,; EPIC study investigators. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol 2011; 87: 338-48.
57. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A,. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115: 2364-71.
58. Pennell D, Carpenter J, Roughton M, Cabantchik Z,. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson 2011; 13: 45.
59. Pennell D, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li C-K, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A,. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica 2012; 97. [Epub ahead of print].
60. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD,. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116: 537-43.
61. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD,. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol 2010; 85: 818-9.
62. Pathare A, Taher A, Daar S,. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol 2010; 89: 405-9.
63. Kontoghiorghes GJ,. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf 2010; 9: 633-41.
64. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB,. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147: 752-9.
65. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A,. Tailoring iron chelation by iron intake and serum ferritin: the prospective epic study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-66.
66. Davis BA, Porter JB,. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-36.
67. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ,. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-55.
68. Mant J, Al-Mohammad A, Swain S, Laramee P,. Management of chronic heart failure in adults: synopsis of the National Institute for Health and Clinical Excellence guideline. Ann Intern Med 2011; 155: 252-9.
69. Aessopos A, Farmakis D, Andreopoulos A, Tsironi M,. Assessment and treatment of cardiac iron overload in thalassemia. Hemoglobin 2009; 33 (Suppl 1): S87-92.
70. Viprakasit V, Lee-Lee C, Chong QT, Lin KH, Khuhapinant A,. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009; 90: 435-45.
71. Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S,. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93: 741-52.
72. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A,. Iron overload. In:, Eleftheriou A, editor. Guidelines for the clinical management of thalassemia. Nicosia, Cyprus: Thalassemia International Federation; 2008. p. 33-63.
73. Cogliandro T, Derchi G, Mancuso L, Mayer MC, Pannone B, Pepe A, Pili M, Bina P, Cianciulli P, De Sanctis V, Maggio A,. Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown) 2008; 9: 515-25.
74. Kremastinos DT, Farmakis D,. Iron overload cardiomyopathy in clinical practice. Circulation 2011; 124: 2253-63.
75. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ,. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8.
76. Donabedian A,. The quality of care. How can it be assessed? JAMA 1988; 260: 1743-8.
77. Abergel RJ, Raymond KN,. Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators. Hemoglobin 2011; 35: 276-90.
78. Carpenter JP, Taigang H, Kirk P, Anderson LJ, Porter J, Fernandes JL, Pennell D,. Worldwide survy of T2* cardiovascular magnetic resonance in thalassaemia. J Cardiovasc Magn Reson 2011; 13 (Suppl 1): O15.
79. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, Liu PP, Backx PH,. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: 1187-94.
80. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A,. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica 2011; 96: 48-54.